PDMS and PFO is effective as tamponade

Article

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

An investigation led by Dr Stefano Zenoni, Bergamno Hospital, Bergamo, Italy, aimed to evaluate ocular tolerance and efficacy of short-term tamponade with double-filling of PDMS and perfluoro-n-octane (PFO) in 30 patients. Double filling with 30% PFO and 70% PDMS was performed for a mean period of 23 days. Follow-up visits were scheduled for 1 week, 1 month and 3 months postoperatively. The main outcome measures included visual acuity, intraocular pressure (IOP), PVR reprofileration and electrophysiological parameters.

Of the 30 patients, 14 experienced improved postoperative visual acuity, 12 patients maintained preoperative visual acuity and 4 patients had a decrease in visual acuity. The average postoperative IOP was 19.7 mmHg. Nine patients experienced an increase in IOP, which was later treated with topical drops or systematic carbonic anhydrase.

Additionally, the researchers found a statistically significant difference in the data obtained with the electroretinogram (ERG) between week 4 and 8 of the follow-up period. There were no electroretinographic traces of retinal toxicity and there was a low occurrence of PVR reproliferation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.